SecBot SecBot
8-K ·Filed Nov 2, 2026

NRXP

NRX Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed14d 18h ago SEC0001437749-26-034284
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

Monitor the company's first commercial sales and revenue disclosures for Preservative-Free Ketamine in upcoming quarterly filings. The product addresses a known shortage, but the addressable market size and pricing are not disclosed.

DirectionBullish
Confidencehigh
Horizonweeks

Preservative-Free Ketamine

◆ Mixed Named in this 8-K
Impact
Phase
Approved (ANDA)
Time to market
Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
Next catalyst
None dated

What to watchThe ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$2.17
T+0 close · Nov 2, 2026 · via day close
Latest settled
+9.68%
T+5 · $2.38 · next T+20 in 14d
Vs SPY
+9.60%
α at T+5
Latest observation
+1.61%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $2.17entry
  2. T+1 · 14d ago +3.23%α +2.93% · $2.24
  3. T+5 · 8d ago +9.68%α +9.60% · $2.38
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals announced FDA approval of its ANDA for Preservative-Free Ketamine, ahead of the November 10, 2026 GDUFA goal date. The product is a preservative-free formulation of ketamine manufactured in the U.S. with Nephron Pharmaceuticals, addressing a drug shortage. The company has commercial supply on hand and can now label and supply hospitals and clinics.

Key Facts

  • FDA approved NRx's ANDA for Preservative-Free Ketamine on October 30, 2026, ahead of the November 10, 2026 GDUFA goal date.
  • The product contains no benzethonium chloride (BZT), a preservative not designated as GRAS by the FDA.
  • Ketamine injection has been in short supply since 2018 and is on the FDA drug shortage list.
  • NRx has manufactured commercial supply on hand and can now label and supply American hospitals and clinics.
  • Manufacturing is done in the U.S. with Nephron Pharmaceuticals in West Columbia, South Carolina using blow-fill-seal technology.
  • NRx market cap is $115M; the company is a clinical-stage biopharma with no prior commercial revenue from this product.

Financial Impact

FDA approval of a drug on the shortage list with commercial supply on hand; no revenue or pricing data disclosed. The approval opens a new revenue stream for a pre-revenue company.

revenueproduct sales

Risk Factors

  • No financial data or revenue guidance provided in the filing; commercial success is unproven.
  • The company is clinical-stage with no prior commercial revenue; execution risk in manufacturing and distribution.
  • Competition from other ketamine suppliers may limit market share.
  • The company's other pipeline candidates (NRX-100, NRX-101) remain in clinical development with regulatory and commercial risk.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-034284
Exhibit: ex_1035048.htm0001437749-26-034284
Document: 0001437749-26-034284-index-headers.html0001437749-26-034284
Document: 0001437749-26-034284-index.html0001437749-26-034284
Document: 0001437749-26-034284.txt0001437749-26-034284

Track record

22 reports on NRXP

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Viewing Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026